Loading page
Loading page
Loading substance route
Effects vary widely by individual, dose, and context.
The head space of 2C-C is described by many as one which is both insightful and relatively normal in its thought processes even at moderate to high dosages.
The visual geometry of 2C-C can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. They can be comprehensively described as structured in their organization, organic in geometric style, intricate in complexity, large in size, slow and smooth in motion, colourful in scheme, glossy in colour, equally blurred and sharp in their edges and equally rounded and angular in their corners. They give off a contradictory natural and synthetic feel at higher dosages. This substance seems more likely to result in states of Level 8B visual geometry over Level 8A.
2C-C produces a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics, particularly in comparison to other substances within the phenethylamine family.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
While anecdotal reports suggest 2C-C is not habit-forming and desire to use may decrease with repeated use, rodent studies have demonstrated reinforcing effects including conditioned place preference and self-administration, suggesting some misuse potential that differs from typical psychedelics.
Anecdotal evidence suggests 2C-C is not physically addictive. No withdrawal syndrome has been documented.
The exact toxic dose is unknown. No formal toxicity studies have been conducted to determine a lethal dose in humans or establish an LD50.
Neurotoxicity has been observed at high doses in rodent studies; the relevance to typical human recreational doses is unknown.
Acute cardiovascular stress including increased blood pressure and heart rate occurs during intoxication, though heart rate elevation may be less pronounced compared to related phenethylamines.
The chance of entering a psychotic or very confused state is relatively low compared to other psychedelics. 2C-C is considered a clear-headed psychedelic overall, though temporary psychosis, paranoia, delusional thinking, and panic attacks remain possible, particularly in individuals with pre-existing mental health conditions.
May lower seizure threshold. Contraindicated in individuals with epilepsy or seizure disorders.
2C-C was first synthesized in 1983 by Alice C. Cheng and Neal Castagnoli Jr. at the University of California, San Francisco. The compound was not originally created for its psychoactive properties; rather, it was produced as an intermediate during their investigation of 6-hydroxydopamine analogs…
Prohibited under a blanket ban covering all substituted phenethylamines, including the entire 2C-X family.
Listed on Portaria SVS/MS nº 344 since February 18, 2014. Possession, production, and sale are prohibited.
Added to China's list of controlled substances in October 2015.
Prohibited under a December 2014 government decree on psychoactive substances banned from the consumer market.
Added to Israel's list of controlled substances in December 2008. Purchase, sale, and possession are illegal.
Classified as a Schedule I controlled substance under Latvian drug legislation.
Specifically named as a controlled substance under Verzeichnis E of Swiss narcotics legislation.
Controlled under the Misuse of Drugs Act 1971 via the phenethylamine catch-all clause. Class A substances carry the most severe penalties under UK drug law.
Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). The NPSV implementing regulation explicitly prohibits all substituted phenethylamines under Schedule II.
Controlled under the Controlled Drugs and Substances Act as of October 31, 2016, classified as a derivative of 2,5-dimethoxyphenethylamine.
Not listed as a controlled substance under Danish law as of available information.
Listed in Schedule I of the Betäubungsmittelgesetz (Narcotics Act) since December 13, 2014. Manufacturing, possession, import, export, purchase, sale, procurement, and dispensing require a license.
Controlled under the Pharmaceutical Affairs Law as a designated substance. Possession and sale are prohibited.
Classified as a health hazard since March 1, 2005 under regulation SFS 2005:26, pursuant to the Act on the Prohibition of Certain Goods Dangerous to Health (Lagen om förbud mot vissa hälsofarliga varor). Sale and possession are prohibited.
Classified as a drug under Turkish law. Possession, production, supply, and import are prohibited.
Federally controlled under the Controlled Substances Act since July 9, 2012, pursuant to the Food and Drug Administration Safety and Innovation Act. Possession, distribution, and manufacture are illegal without DEA authorization. Additionally scheduled at state level in Alabama (Schedule I since February 2013), Oklahoma (Schedule I since May 2011), Pennsylvania (Schedule I), and Vermont (classified under hallucinogenic drugs since July 2012).
25 sources cited
